NEO-AEGIS

NCT01726452 📎

Regimen

Experimental
CROSS trimodality (preop carboplatin/paclitaxel + 41.4 Gy RT + surgery)
Control
perioperative chemotherapy (MAGIC-modified ECF/ECX/EOF/EOX pre-2018, then FLOT from 2018)

Population

cT2-3 N0-3 M0 adenocarcinoma of oesophagus or oesophagogastric junction

Key finding

mOS 48.0 vs 49.2 mo; 3y OS 55% vs 57% (HR 1.03, P=0.82). pCR and R0 higher with CROSS but OS/DFS equivalent.

Source: PMID 37734399

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.113)